FDA calls on IG to probe Avandia panel conflict
The FDA is looking to higher-ups for help sorting out a potential conflict of interest on the recent Avandia advisory panel. After news emerged last week that one panelist, endocrinologist David Capuzzi, had been paid to speak on behalf of a GlaxoSmithKline ( NYSE: GSK ) product, agency officials asked Health and Human Services investigators to look into the situation. Capuzzi tells the Wall Street Journal that he had served as a paid speaker for GSK, but not on behalf of Avandia. It’s unclear what Capuzzi told the FDA about that financial relationship. The company
